Hot Features
프리미엄
Myogen (MYOG)
NASDAQ
실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
Gilead Sciences, Inc. (Nasdaq:GILD) announced today that it has completed its acquisition of Myogen, Inc. (Nasdaq:MYOG). On November 17, 2006, Gilead caused one of its...
Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of...
Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of...
Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of...
CHICAGO, Oct. 2 /PRNewswire/ -- Seven Summits Research Releases NewsBites on key stocks. Seven Summits Strategic Investments NewsBites are available to all investors at...
Gilead Sciences, Inc. (Nasdaq:GILD) and Myogen, Inc. (Nasdaq:MYOG) announced today that the companies have signed a definitive agreement under which Gilead plans to acquire...
Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular...
Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular...
The American Lung Association and Myogen, Inc. (Nasdaq: MYOG) today announced that they will collaborate on a new public awareness initiative to educate the public about pulmonary...
Myogen, Inc. (Nasdaq:MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular...
| 기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
